A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions
Abstract Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and today is used extensively. Recent studies in vaccinated populations indicate a major PCV2 genotype shift from the predominant PCV2 genotype 2b towards 2d. The aims of this study were...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2017-01, Vol.35 (2), p.248-254 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 254 |
|---|---|
| container_issue | 2 |
| container_start_page | 248 |
| container_title | Vaccine |
| container_volume | 35 |
| creator | Opriessnig, Tanja Xiao, Chao-Ting Halbur, Patrick G Gerber, Priscilla F Matzinger, Shannon R Meng, Xiang-Jin |
| description | Abstract Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and today is used extensively. Recent studies in vaccinated populations indicate a major PCV2 genotype shift from the predominant PCV2 genotype 2b towards 2d. The aims of this study were to determine the ability of the commercial inactivated PCV2a vaccine Circovac® to protect pigs against experimental challenge with a 2013 PCV2d strain and prevent transmission. Thirty-eight pigs were randomly divided into four groups with 9–10 pigs per group: NEG (sham-vaccinated, sham-challenged), VAC (PCV2a-vaccinated, sham-challenged), VAC + CHAL (PCV2a-vaccinated and PCV2d-challenged), and CHAL (sham-vaccinated, PCV2d-challenged). Vaccination was done at 3 weeks of age using Circovac® according to label instructions. The CHAL and VAC + CHAL groups were challenged with PCV2d at 7 weeks of age and all pigs were necropsied 21 days post-challenge (dpc). The VAC-CHAL pigs seroconverted to PCV2 by 21 days post vaccination (dpv). At PCV2d challenge on 28 dpv, 3/9 VAC and 1/9 VAC + CHAL pigs were seropositive. NEG pigs remained seronegative for the duration of the study. Vaccination significantly reduced PCV2d viremia (VAC + CHAL) at dpc 14 and 21, PCV2d fecal shedding at dpc 14 and 21 and PCV2d nasal shedding at dpc 7, 14 and 21 compared to CHAL pigs. Vaccination significantly reduced mean PCV2 antigen load in lymph nodes in VAC + CHAL pigs compared to CHAL pigs. When pooled serum or feces collected from VAC + CHAL and CHAL pigs at dpc 21 were used to expose single-housed PCV2 naïve pigs, a pooled fecal sample from CHAL pigs contained infectious PCV2 whereas this was not the case for VAC + CHAL pigs suggesting reduction of PCV2d transmission by vaccination. Under the study conditions, the PCV2a-based vaccine was effective in reducing PCV2d viremia, tissue loads, shedding and transmission indicating that PCV2a vaccination should be effective in PCV2d-infected herds. |
| doi_str_mv | 10.1016/j.vaccine.2016.11.085 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5221148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X16311574</els_id><sourcerecordid>2000468152</sourcerecordid><originalsourceid>FETCH-LOGICAL-c583t-ea2152b5fe46da45bec9dd914d586e06cadc393b429e9a2d1e1899cb55ec66b33</originalsourceid><addsrcrecordid>eNqFkstuEzEUhkcIREvhEUCW2JTFBN8z3hRVETepEkhcxM7y2Cepw4w92DMReSYWPAQvhkPSAt10Zdn-zu__-PxV9ZjgGcFEPl_PNsZaH2BGy3ZGyAw34k51TJo5q6kgzd3qGFPJa07wl6PqQc5rjLFgRN2vjuhcESUZP65-nCMb-x6S9aZDQ0w7SWR9snHj05TR6fvF52do3A6AqKlbk8Ghw8sogZssZFQQWk59gt4bZIJD-RKc82H1ZzMk2EAYr7gxmZB7n7OPAY0RBfPr5wbQ4FcZTcFBQvB9gOT7UlM82RicHwubH1b3lqbL8OiwnlSfXr38uHhTX7x7_XZxflFb0bCxBkOJoK1YApfOcNGCVc4pwp1oJGBpjbNMsZZTBcpQR4A0StlWCLBStoydVGd73WFqe3C2-Eim00OxZNJWR-P1_zfBX-pV3GhBKSG8KQKnB4EUv02QR13atdB1JkCcsqZlElw2xeWtKGm4ZFI2nBT06Q10HacUyk8USgiGFRaqUGJP2RRzTrC89k2w3iVHr_VhfnqXHE2ILskpdU_-bfq66ioqBXixB6B8_cZD0tl6CBZcmbsdtYv-1ifObijYzgdvTfcVtpD_dqMz1Vh_2MV3l14iGSFiztlv1ArwRg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1855309059</pqid></control><display><type>article</type><title>A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Opriessnig, Tanja ; Xiao, Chao-Ting ; Halbur, Patrick G ; Gerber, Priscilla F ; Matzinger, Shannon R ; Meng, Xiang-Jin</creator><creatorcontrib>Opriessnig, Tanja ; Xiao, Chao-Ting ; Halbur, Patrick G ; Gerber, Priscilla F ; Matzinger, Shannon R ; Meng, Xiang-Jin</creatorcontrib><description>Abstract Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and today is used extensively. Recent studies in vaccinated populations indicate a major PCV2 genotype shift from the predominant PCV2 genotype 2b towards 2d. The aims of this study were to determine the ability of the commercial inactivated PCV2a vaccine Circovac® to protect pigs against experimental challenge with a 2013 PCV2d strain and prevent transmission. Thirty-eight pigs were randomly divided into four groups with 9–10 pigs per group: NEG (sham-vaccinated, sham-challenged), VAC (PCV2a-vaccinated, sham-challenged), VAC + CHAL (PCV2a-vaccinated and PCV2d-challenged), and CHAL (sham-vaccinated, PCV2d-challenged). Vaccination was done at 3 weeks of age using Circovac® according to label instructions. The CHAL and VAC + CHAL groups were challenged with PCV2d at 7 weeks of age and all pigs were necropsied 21 days post-challenge (dpc). The VAC-CHAL pigs seroconverted to PCV2 by 21 days post vaccination (dpv). At PCV2d challenge on 28 dpv, 3/9 VAC and 1/9 VAC + CHAL pigs were seropositive. NEG pigs remained seronegative for the duration of the study. Vaccination significantly reduced PCV2d viremia (VAC + CHAL) at dpc 14 and 21, PCV2d fecal shedding at dpc 14 and 21 and PCV2d nasal shedding at dpc 7, 14 and 21 compared to CHAL pigs. Vaccination significantly reduced mean PCV2 antigen load in lymph nodes in VAC + CHAL pigs compared to CHAL pigs. When pooled serum or feces collected from VAC + CHAL and CHAL pigs at dpc 21 were used to expose single-housed PCV2 naïve pigs, a pooled fecal sample from CHAL pigs contained infectious PCV2 whereas this was not the case for VAC + CHAL pigs suggesting reduction of PCV2d transmission by vaccination. Under the study conditions, the PCV2a-based vaccine was effective in reducing PCV2d viremia, tissue loads, shedding and transmission indicating that PCV2a vaccination should be effective in PCV2d-infected herds.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2016.11.085</identifier><identifier>PMID: 27919634</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Allergy and Immunology ; Animals ; Antigens ; Blood - virology ; blood serum ; Circoviridae Infections - pathology ; Circoviridae Infections - prevention & control ; Circoviridae Infections - veterinary ; Circovirus - immunology ; Epidemics ; Feces ; Feces - virology ; Funding ; genotype ; herds ; Hogs ; Infections ; Lymph nodes ; Lymph Nodes - virology ; necropsy ; nose ; PCV2 ; PCV2d ; Porcine circovirus ; Porcine circovirus-2 ; Random Allocation ; Seroconversion ; seroprevalence ; Swine ; Swine Diseases - prevention & control ; Time Factors ; Transmission ; Vaccination ; Vaccine efficacy ; Vaccines ; Vaccines, Inactivated - administration & dosage ; Vaccines, Inactivated - immunology ; Viral Vaccines - administration & dosage ; Viral Vaccines - immunology ; viremia ; Viremia - prevention & control ; Viremia - veterinary ; Virus Shedding ; Viruses</subject><ispartof>Vaccine, 2017-01, Vol.35 (2), p.248-254</ispartof><rights>The Author(s)</rights><rights>2016 The Author(s)</rights><rights>Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><rights>Copyright Elsevier Limited Jan 5, 2017</rights><rights>2016 The Author(s) 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c583t-ea2152b5fe46da45bec9dd914d586e06cadc393b429e9a2d1e1899cb55ec66b33</citedby><cites>FETCH-LOGICAL-c583t-ea2152b5fe46da45bec9dd914d586e06cadc393b429e9a2d1e1899cb55ec66b33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X16311574$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27919634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Opriessnig, Tanja</creatorcontrib><creatorcontrib>Xiao, Chao-Ting</creatorcontrib><creatorcontrib>Halbur, Patrick G</creatorcontrib><creatorcontrib>Gerber, Priscilla F</creatorcontrib><creatorcontrib>Matzinger, Shannon R</creatorcontrib><creatorcontrib>Meng, Xiang-Jin</creatorcontrib><title>A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and today is used extensively. Recent studies in vaccinated populations indicate a major PCV2 genotype shift from the predominant PCV2 genotype 2b towards 2d. The aims of this study were to determine the ability of the commercial inactivated PCV2a vaccine Circovac® to protect pigs against experimental challenge with a 2013 PCV2d strain and prevent transmission. Thirty-eight pigs were randomly divided into four groups with 9–10 pigs per group: NEG (sham-vaccinated, sham-challenged), VAC (PCV2a-vaccinated, sham-challenged), VAC + CHAL (PCV2a-vaccinated and PCV2d-challenged), and CHAL (sham-vaccinated, PCV2d-challenged). Vaccination was done at 3 weeks of age using Circovac® according to label instructions. The CHAL and VAC + CHAL groups were challenged with PCV2d at 7 weeks of age and all pigs were necropsied 21 days post-challenge (dpc). The VAC-CHAL pigs seroconverted to PCV2 by 21 days post vaccination (dpv). At PCV2d challenge on 28 dpv, 3/9 VAC and 1/9 VAC + CHAL pigs were seropositive. NEG pigs remained seronegative for the duration of the study. Vaccination significantly reduced PCV2d viremia (VAC + CHAL) at dpc 14 and 21, PCV2d fecal shedding at dpc 14 and 21 and PCV2d nasal shedding at dpc 7, 14 and 21 compared to CHAL pigs. Vaccination significantly reduced mean PCV2 antigen load in lymph nodes in VAC + CHAL pigs compared to CHAL pigs. When pooled serum or feces collected from VAC + CHAL and CHAL pigs at dpc 21 were used to expose single-housed PCV2 naïve pigs, a pooled fecal sample from CHAL pigs contained infectious PCV2 whereas this was not the case for VAC + CHAL pigs suggesting reduction of PCV2d transmission by vaccination. Under the study conditions, the PCV2a-based vaccine was effective in reducing PCV2d viremia, tissue loads, shedding and transmission indicating that PCV2a vaccination should be effective in PCV2d-infected herds.</description><subject>Age</subject><subject>Allergy and Immunology</subject><subject>Animals</subject><subject>Antigens</subject><subject>Blood - virology</subject><subject>blood serum</subject><subject>Circoviridae Infections - pathology</subject><subject>Circoviridae Infections - prevention & control</subject><subject>Circoviridae Infections - veterinary</subject><subject>Circovirus - immunology</subject><subject>Epidemics</subject><subject>Feces</subject><subject>Feces - virology</subject><subject>Funding</subject><subject>genotype</subject><subject>herds</subject><subject>Hogs</subject><subject>Infections</subject><subject>Lymph nodes</subject><subject>Lymph Nodes - virology</subject><subject>necropsy</subject><subject>nose</subject><subject>PCV2</subject><subject>PCV2d</subject><subject>Porcine circovirus</subject><subject>Porcine circovirus-2</subject><subject>Random Allocation</subject><subject>Seroconversion</subject><subject>seroprevalence</subject><subject>Swine</subject><subject>Swine Diseases - prevention & control</subject><subject>Time Factors</subject><subject>Transmission</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Vaccines, Inactivated - administration & dosage</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Viral Vaccines - administration & dosage</subject><subject>Viral Vaccines - immunology</subject><subject>viremia</subject><subject>Viremia - prevention & control</subject><subject>Viremia - veterinary</subject><subject>Virus Shedding</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkstuEzEUhkcIREvhEUCW2JTFBN8z3hRVETepEkhcxM7y2Cepw4w92DMReSYWPAQvhkPSAt10Zdn-zu__-PxV9ZjgGcFEPl_PNsZaH2BGy3ZGyAw34k51TJo5q6kgzd3qGFPJa07wl6PqQc5rjLFgRN2vjuhcESUZP65-nCMb-x6S9aZDQ0w7SWR9snHj05TR6fvF52do3A6AqKlbk8Ghw8sogZssZFQQWk59gt4bZIJD-RKc82H1ZzMk2EAYr7gxmZB7n7OPAY0RBfPr5wbQ4FcZTcFBQvB9gOT7UlM82RicHwubH1b3lqbL8OiwnlSfXr38uHhTX7x7_XZxflFb0bCxBkOJoK1YApfOcNGCVc4pwp1oJGBpjbNMsZZTBcpQR4A0StlWCLBStoydVGd73WFqe3C2-Eim00OxZNJWR-P1_zfBX-pV3GhBKSG8KQKnB4EUv02QR13atdB1JkCcsqZlElw2xeWtKGm4ZFI2nBT06Q10HacUyk8USgiGFRaqUGJP2RRzTrC89k2w3iVHr_VhfnqXHE2ILskpdU_-bfq66ioqBXixB6B8_cZD0tl6CBZcmbsdtYv-1ifObijYzgdvTfcVtpD_dqMz1Vh_2MV3l14iGSFiztlv1ArwRg</recordid><startdate>20170105</startdate><enddate>20170105</enddate><creator>Opriessnig, Tanja</creator><creator>Xiao, Chao-Ting</creator><creator>Halbur, Patrick G</creator><creator>Gerber, Priscilla F</creator><creator>Matzinger, Shannon R</creator><creator>Meng, Xiang-Jin</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><scope>5PM</scope></search><sort><creationdate>20170105</creationdate><title>A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions</title><author>Opriessnig, Tanja ; Xiao, Chao-Ting ; Halbur, Patrick G ; Gerber, Priscilla F ; Matzinger, Shannon R ; Meng, Xiang-Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c583t-ea2152b5fe46da45bec9dd914d586e06cadc393b429e9a2d1e1899cb55ec66b33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Age</topic><topic>Allergy and Immunology</topic><topic>Animals</topic><topic>Antigens</topic><topic>Blood - virology</topic><topic>blood serum</topic><topic>Circoviridae Infections - pathology</topic><topic>Circoviridae Infections - prevention & control</topic><topic>Circoviridae Infections - veterinary</topic><topic>Circovirus - immunology</topic><topic>Epidemics</topic><topic>Feces</topic><topic>Feces - virology</topic><topic>Funding</topic><topic>genotype</topic><topic>herds</topic><topic>Hogs</topic><topic>Infections</topic><topic>Lymph nodes</topic><topic>Lymph Nodes - virology</topic><topic>necropsy</topic><topic>nose</topic><topic>PCV2</topic><topic>PCV2d</topic><topic>Porcine circovirus</topic><topic>Porcine circovirus-2</topic><topic>Random Allocation</topic><topic>Seroconversion</topic><topic>seroprevalence</topic><topic>Swine</topic><topic>Swine Diseases - prevention & control</topic><topic>Time Factors</topic><topic>Transmission</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Vaccines, Inactivated - administration & dosage</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Viral Vaccines - administration & dosage</topic><topic>Viral Vaccines - immunology</topic><topic>viremia</topic><topic>Viremia - prevention & control</topic><topic>Viremia - veterinary</topic><topic>Virus Shedding</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Opriessnig, Tanja</creatorcontrib><creatorcontrib>Xiao, Chao-Ting</creatorcontrib><creatorcontrib>Halbur, Patrick G</creatorcontrib><creatorcontrib>Gerber, Priscilla F</creatorcontrib><creatorcontrib>Matzinger, Shannon R</creatorcontrib><creatorcontrib>Meng, Xiang-Jin</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Opriessnig, Tanja</au><au>Xiao, Chao-Ting</au><au>Halbur, Patrick G</au><au>Gerber, Priscilla F</au><au>Matzinger, Shannon R</au><au>Meng, Xiang-Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2017-01-05</date><risdate>2017</risdate><volume>35</volume><issue>2</issue><spage>248</spage><epage>254</epage><pages>248-254</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract Porcine circovirus type 2 (PCV2) vaccination has been effective in protecting pigs from clinical disease and today is used extensively. Recent studies in vaccinated populations indicate a major PCV2 genotype shift from the predominant PCV2 genotype 2b towards 2d. The aims of this study were to determine the ability of the commercial inactivated PCV2a vaccine Circovac® to protect pigs against experimental challenge with a 2013 PCV2d strain and prevent transmission. Thirty-eight pigs were randomly divided into four groups with 9–10 pigs per group: NEG (sham-vaccinated, sham-challenged), VAC (PCV2a-vaccinated, sham-challenged), VAC + CHAL (PCV2a-vaccinated and PCV2d-challenged), and CHAL (sham-vaccinated, PCV2d-challenged). Vaccination was done at 3 weeks of age using Circovac® according to label instructions. The CHAL and VAC + CHAL groups were challenged with PCV2d at 7 weeks of age and all pigs were necropsied 21 days post-challenge (dpc). The VAC-CHAL pigs seroconverted to PCV2 by 21 days post vaccination (dpv). At PCV2d challenge on 28 dpv, 3/9 VAC and 1/9 VAC + CHAL pigs were seropositive. NEG pigs remained seronegative for the duration of the study. Vaccination significantly reduced PCV2d viremia (VAC + CHAL) at dpc 14 and 21, PCV2d fecal shedding at dpc 14 and 21 and PCV2d nasal shedding at dpc 7, 14 and 21 compared to CHAL pigs. Vaccination significantly reduced mean PCV2 antigen load in lymph nodes in VAC + CHAL pigs compared to CHAL pigs. When pooled serum or feces collected from VAC + CHAL and CHAL pigs at dpc 21 were used to expose single-housed PCV2 naïve pigs, a pooled fecal sample from CHAL pigs contained infectious PCV2 whereas this was not the case for VAC + CHAL pigs suggesting reduction of PCV2d transmission by vaccination. Under the study conditions, the PCV2a-based vaccine was effective in reducing PCV2d viremia, tissue loads, shedding and transmission indicating that PCV2a vaccination should be effective in PCV2d-infected herds.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>27919634</pmid><doi>10.1016/j.vaccine.2016.11.085</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2017-01, Vol.35 (2), p.248-254 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5221148 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Age Allergy and Immunology Animals Antigens Blood - virology blood serum Circoviridae Infections - pathology Circoviridae Infections - prevention & control Circoviridae Infections - veterinary Circovirus - immunology Epidemics Feces Feces - virology Funding genotype herds Hogs Infections Lymph nodes Lymph Nodes - virology necropsy nose PCV2 PCV2d Porcine circovirus Porcine circovirus-2 Random Allocation Seroconversion seroprevalence Swine Swine Diseases - prevention & control Time Factors Transmission Vaccination Vaccine efficacy Vaccines Vaccines, Inactivated - administration & dosage Vaccines, Inactivated - immunology Viral Vaccines - administration & dosage Viral Vaccines - immunology viremia Viremia - prevention & control Viremia - veterinary Virus Shedding Viruses |
| title | A commercial porcine circovirus (PCV) type 2a-based vaccine reduces PCV2d viremia and shedding and prevents PCV2d transmission to naïve pigs under experimental conditions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A02%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20commercial%20porcine%20circovirus%20(PCV)%20type%202a-based%20vaccine%20reduces%20PCV2d%20viremia%20and%20shedding%20and%20prevents%20PCV2d%20transmission%20to%20na%C3%AFve%20pigs%20under%20experimental%20conditions&rft.jtitle=Vaccine&rft.au=Opriessnig,%20Tanja&rft.date=2017-01-05&rft.volume=35&rft.issue=2&rft.spage=248&rft.epage=254&rft.pages=248-254&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2016.11.085&rft_dat=%3Cproquest_pubme%3E2000468152%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1855309059&rft_id=info:pmid/27919634&rft_els_id=S0264410X16311574&rfr_iscdi=true |